产品说明书
SB 699551 dihydrochloride
 |
同义名 : | SB-699551 |
| CAS号 : | 864741-95-7 | |
| 货号 : | A822692 | |
| 分子式 : | C34H47Cl2N3O | |
| 纯度 : | 98% | |
| 分子量 : | 584.663 | |
| MDL号 : | MFCD11112202 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 120 mg/mL(205.25 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | SB-699551 is a 5-HT5A receptor antagonist. SB-699551 (0.1 mg/kg) decreased lever-press conditioned responses (CR) during short-term (STM; 1.5-h) or (3.0 mg/kg) long-term memory (LTM; 24-h); relative to the vehicle animals. SB-699551 (0.3 mg/kg) alone also produced amnesia-like effect[1]. SB-699551-A showed an anxiolytic-like property in the ultrasonic vocalization test[2]. SB-699551 has efficiency in ameliorating ketamine-induced impairments on the ASST (attentional set-shifting task) and NORT (ovel object recognition task)[3]. SB-699551 ((1-10mg/kg, i.p.) nor SB-269970 (5-HT(7) antagonist, 1-10mg/kg, i.p.) reduced the 5-HTP (5-hydroxytryptophan) and HAL(haloperidol)-induced bradykinesia or catalepsy[4]. SB-699551 significantly reduced the antinociceptive effect of both WIN 55,212-2 and morphine[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.71mL 0.34mL 0.17mL |
8.55mL 1.71mL 0.86mL |
17.10mL 3.42mL 1.71mL |
| 参考文献 |
|---|